NCT01356160 - GS-5885 Alone or in Combination With GS-9451 With Peginterferon Alfa 2a and Ribavirin in Treatment Chronic Genotype 1 Hepatitis C Virus | Biotech Hunter

Enrollment

351

Participants

Timeline

Start Date

July 31, 2011

Primary Completion Date

June 30, 2013

Study Completion Date

June 30, 2013

Conditions

Hepatitis C, Chronic

Interventions

DRUG

GS-5885

tablet, 30 mg QD

DRUG

GS-9451

tablet, 200 mg QD

BIOLOGICAL

peginterferon alfa-2a

(solution for injection) 180 µg/week

DRUG

ribavirin tablet

ribavirin tablet (weight based: 1000 mg/day \<75 kg; 1200 mg/day ≥ 75 kg) divided twice daily (BID)

DRUG

GS-9451 Placebo

Placebo to match GS-9451 QD

Trial Locations (23)

4029

Herston

11030

Manhasset

11375

Forest Hills

21202

Baltimore

21229

Baltimore

22031

Fairfax

27710

Durham

34209

Bradenton

37211

Nashville

45267

Cincinnati

64131

Kansas City

76012

Arlington

77030

Houston

78215

San Antonio

80045

Aurora

80110

Englewood

85724

Tucson

90211

Beverly Hills

92118

Coronado

92123

San Diego

92626

Costa Mesa

01805

Burlington

00927

San Juan